Publications

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

Zappasodi R

Cancer Res. 2010 Sep 30;70(22):9062-72. doi: 10.1158/0008-5472.CAN-10-1825

Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.

Viviani S

Leuk Lymphoma. 51(7):1251-9. doi: 10.3109/10428194.2010.486090

Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature.

Lavazza C

Blood. 2010 Jan 14;115(11):2231-40. doi: 10.1182/blood-2009-08-239632

Radioimmunotherapy and secondary leukemia: a case report.

Magni M

Leuk Res. 2009 May 15;34(1):e1-4. doi: 10.1016/j.leukres.2009.04.028

Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up.

Magni M

Bone Marrow Transplant. 2009 Oct 12;45(6):1119-20. doi: 10.1038/bmt.2009.294

Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status.

Ruella M

Bone Marrow Transplant. 2009 Oct 19;45(3):505-12. doi: 10.1038/bmt.2009.297

Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.

De Filippi P

Br J Haematol. 2009 Sep 22;147(5):706-9. doi: 10.1111/j.1365-2141.2009.07894.x

A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.

Righi M

Lab Invest. 2009 Aug 3;89(9):1063-70. doi: 10.1038/labinvest.2009.76

Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).

Chiesa C

Eur J Nucl Med Mol Imaging. 2009 May 20;36(11):1745-57. doi: 10.1007/s00259-009-1141-x

Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.

Dodero A

Blood. 2009 Feb 11;113(19):4771-9. doi: 10.1182/blood-2008-10-183723